Lucid Diagnostics (NASDAQ:LUCD - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at Needham & Company LLC in a research note issued on Friday,Benzinga reports. They currently have a $3.00 target price on the stock. Needham & Company LLC's price objective suggests a potential upside of 177.78% from the company's current price.
A number of other research analysts have also commented on LUCD. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $2.00 price objective on shares of Lucid Diagnostics in a research report on Wednesday, March 26th. BTIG Research set a $2.00 price objective on Lucid Diagnostics in a research report on Tuesday, March 25th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Lucid Diagnostics has an average rating of "Buy" and an average target price of $3.40.
Get Our Latest Stock Analysis on Lucid Diagnostics
Lucid Diagnostics Price Performance
LUCD stock traded down $0.05 on Friday, reaching $1.08. 447,231 shares of the company were exchanged, compared to its average volume of 437,256. The firm has a market capitalization of $98.01 million, a PE ratio of -0.95 and a beta of 1.26. Lucid Diagnostics has a 12 month low of $0.63 and a 12 month high of $1.80. The stock's fifty day moving average price is $1.42 and its 200 day moving average price is $1.07.
Hedge Funds Weigh In On Lucid Diagnostics
A number of hedge funds have recently modified their holdings of LUCD. Sargent Investment Group LLC acquired a new position in Lucid Diagnostics during the fourth quarter worth $442,000. Citadel Advisors LLC bought a new position in Lucid Diagnostics during the 4th quarter valued at about $98,000. Sunbelt Securities Inc. acquired a new position in Lucid Diagnostics in the fourth quarter valued at about $67,000. Geode Capital Management LLC increased its holdings in shares of Lucid Diagnostics by 30.9% during the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company's stock worth $229,000 after buying an additional 65,964 shares in the last quarter. Finally, Lido Advisors LLC raised its stake in shares of Lucid Diagnostics by 40.0% in the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company's stock valued at $115,000 after acquiring an additional 40,000 shares during the last quarter. 74.01% of the stock is owned by institutional investors and hedge funds.
About Lucid Diagnostics
(
Get Free Report)
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Featured Stories
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
